Saurabh MD - Centessa Pharmaceuticals CEO Director
| CNTA Stock | USD 18.19 1.45 8.66% |
Insider
Saurabh MD is CEO Director of Centessa Pharmaceuticals PLC
| Age | 48 |
| Address | 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT |
| Phone | 44 203 9206789 |
| Web | https://www.centessa.com |
Centessa Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2047) % which means that it has lost $0.2047 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4252) %, meaning that it created substantial loss on money invested by shareholders. Centessa Pharmaceuticals' management efficiency ratios could be used to measure how well Centessa Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.44. In addition to that, Return On Capital Employed is expected to decline to -0.56. At present, Centessa Pharmaceuticals' Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.26, whereas Total Assets are forecasted to decline to about 322.4 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Qiyong Liu | Transcode Therapeutics | 60 | |
| Robert Dudley | Transcode Therapeutics | 73 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Anna Moore | Transcode Therapeutics | 62 | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.2 |
Centessa Pharmaceuticals Leadership Team
Elected by the shareholders, the Centessa Pharmaceuticals' board of directors comprises two types of representatives: Centessa Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Centessa. The board's role is to monitor Centessa Pharmaceuticals' management team and ensure that shareholders' interests are well served. Centessa Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Centessa Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tia Bush, Chief Officer | ||
| MD MSc, Ex Devel | ||
| April Dovholuk, Senior Operations | ||
| JD Esq, Senior Communications | ||
| MBA MD, Principal CFO | ||
| David Chao, Chief Officer | ||
| MD MBA, Principal CFO | ||
| Thomas Templeman, Chief Officer | ||
| Joshua MBA, Sr Devel | ||
| David Grainger, Chief Officer | ||
| Saurabh MD, CEO Director | ||
| Patrick MD, Senior Medicines | ||
| Iqbal LLB, Chief Counsel | ||
| Harris Rotman, Senior Affairs | ||
| Karen Anderson, Chief Officer | ||
| Mario Accardi, President Program | ||
| MSc MD, Executive Development | ||
| John CPA, CFO Officer |
Centessa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Centessa Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (23.59) % | ||||
| Current Valuation | 1.77 B | ||||
| Shares Outstanding | 131.84 M | ||||
| Shares Owned By Insiders | 1.35 % | ||||
| Shares Owned By Institutions | 92.52 % | ||||
| Number Of Shares Shorted | 2.15 M | ||||
| Price To Book | 4.42 X | ||||
| Price To Sales | 322.06 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Centessa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Centessa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Centessa Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Centessa Pharmaceuticals Plc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Centessa Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Centessa Pharmaceuticals. If investors know Centessa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Centessa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.065 | Return On Assets (0.20) | Return On Equity (0.43) |
The market value of Centessa Pharmaceuticals is measured differently than its book value, which is the value of Centessa that is recorded on the company's balance sheet. Investors also form their own opinion of Centessa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Centessa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Centessa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Centessa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Centessa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Centessa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Centessa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.